top of page

Napo Pharmaceuticals files patent application for crofelemer to mitigate GLP-1 side-effects

owenhaskins

Napo Pharmaceuticals has filed a broad defining provisional patent application with the US Patent and Trademark Office (USPTO) for crofelemer, Jaguar’s novel plant-based FDA-approved gastrointestinal normalising prescription drug, to mitigate the gastrointestinal side effects associated with glucagon-like peptide-1 (GLP-1) receptor agonists and antagonists, together with other incretin-based therapies including glucose-dependent insulinotropic polypeptide (GIP) agonists and antagonists, and glucagon-agonist drugs.


Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting programme, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.


“Gastrointestinal disorders were the most frequently reported adverse effects during clinical trials and real-world experience of GLP-1 receptor agonists. GI adverse events usually develop in 40-70% of patients treated with GLP-1 receptor agonists, although they have sometimes been reported in up to 85%. There are also numerous investigative agents, including incretins and combinations with GLP-1 drugs, both as receptor agonists and antagonists, all of which are associated with significant GI side effects, often in a dose-dependent manner. Our IP strategy includes claims for both commercialized obesity drugs and incretin-based therapies in development. Crofelemer, approved by the FDA under the brand name Mytesi for HIV-related diarrhoea, has demonstrated a significant benefit in improving gastrointestinal symptoms, including diarrhea, abdominal pain and discomfort, incontinence, bloating and constipation, when studied in populations with HIV-related diarrhoea, cancer therapy-related diarrhoea and IBS,” said Lisa Conte, Jaguar’s founder, president, and CEO. “Crofelemer has a safety profile supporting its chronic utilization, and we are excited about crofelemer’s possible potential to normalize specific GI side effects associated with obesity therapies, address patient comfort, and help patient’s stay on their therapy.”

Comments


Weekly Digest

Get a round-up of the main headlines from Bariatric News, directly to your inbox each week.

Thanks for submitting!

Get in touch!
Email: info@bariatricnews.net

©2023 Dendrite Clinical Systems Ltd. All rights reserved.
No part of this website may be reproduced, stored in a retrieval system, transmitted in any form or by any other means without prior written permission from the Managing Editor. The views, comments and opinions expressed within are not necessarily those of Dendrite Clinical Systems or the Editorial Board. Bariatricnews.net is a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

bottom of page